Health and Fitness Health and Fitness
Wed, November 30, 2011
[ Wed, Nov 30th 2011 ] - Market Wire
Watson Launches Generic LIPITOR
Tue, November 29, 2011
Mon, November 28, 2011
Sun, November 27, 2011
Fri, November 25, 2011
Thu, November 24, 2011
Wed, November 23, 2011
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. EST
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011
Sun, November 20, 2011
Fri, November 18, 2011
Thu, November 17, 2011
Wed, November 16, 2011
Tue, November 15, 2011

MELA Sciences to Present at Piper Jaffray 23rd Annual Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. r-jaffray-23rd-annual-healthcare-conference.html
Published in Health and Fitness on Tuesday, November 22nd 2011 at 4:15 GMT by Market Wire   Print publication without navigation


November 22, 2011 07:00 ET

MELA Sciences to Present at Piper Jaffray 23rd Annual Healthcare Conference

IRVINGTON, NY--(Marketwire - Nov 22, 2011) - MELA Sciences, Inc. (NASDAQ: [ MELA ]) announced today that Joseph V. Gulfo, MD, President and CEO, will present at the Piper Jaffray 23rd Annual Healthcare Conference taking place November 29-30 at The New York Palace Hotel. Dr. Gulfo is scheduled to present on Wednesday, November 30, 2011 at 4:30 pm ET.

To access a live webcast of this presentation, visit the investor relations section of [ www.melasciences.com ]. A replay will be available on the company's website for two weeks following the presentation.

About MELA Sciences, Inc.
MELA Sciences is a medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. The company's flagship product, MelaFind®, is intended to be used when a trained dermatologist chooses to obtain additional information to help decide whether to biopsy certain indeterminate pigmented skin lesions. The FDA has approved MelaFind for use in the U.S. It has received the CE Mark for use in the European Union.

For more information on MELA Sciences, visit [ www.melasciences.com ].

Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes," "assumes," "predicts" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved. Actual results may differ materially from our beliefs or expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties facing the company such as those set forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission (the "SEC"). Factors that might cause such a difference include whether MelaFind® achieves market acceptance or becomes commercially viable. Given the uncertainties affecting companies in the medical device industry such as the company, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. The company urges you to carefully review and consider the disclosures found in its filings with the SEC which are available at [ www.sec.gov ] and [ www.melasciences.com ].



Publication Contributing Sources